For Karyopharm Therapeutics Inc. (KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, 2026 promises to be a transformative year as it awaits a key data readout for its flagship asset, Xpovio, in the coming months.
Xpovio (selinexor) belongs to the drug class called selective inhibitors of nuclear export (SINE). It works by targeting a specific protein complex called XPO1, which is responsible for removing tumor suppressor proteins from the cell nucleus. This leads to the accumulation of XPO1 inside the cell, which reinitiates and amplifies its function, leading to apoptosis (cell death) of cancer cells, while largely sparing normal cells. (Source: Drugs.com)
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.